Malignant mesothelioma is an aggressive cancer associated with prior exposure to asbestos and dismal prognosis. Immune checkpoint inhibitor therapy is currently approved by the Food and Drug Administration for pre-treated malignant pleural mesothelioma. We describe a 75-year-old patient with disseminated, progressive malignant mesothelioma receiving 2 cycles of pembrolizumab who presented with generalized muscle weakness, shortness of breath, double vision and ptosis. There was no previous history of cardiovascular disease. The clinical picture, supported by the detection of anti-titin autoantibodies suggested myasthenia gravis (MG). Also, cardiac biomarkers were elevated. Echocardiography showed new severely reduced ejection fraction. A 12-lead resting electrocardiogram (ECG) revealed ST segment elevation in the posterior leads with polymorphic ventricular extrasystoles. Because cardiac catheterization revealed no relevant coronary lesions, immune checkpoint inhibitor-associated myocarditis and MG were suspected. Management and Outcome: The patient was started on steroids. Within a few days of presentation respiratory failure set in and the patient was intubated. Recurrent arrhythmias followed, which were treated by repeated emergency electrical cardioversion. In order to relieve myasthenic symptoms, plasma exchange was initiated and 10 cycles were carried out. This consequently also led to an improvement of myocarditis. Upon discharge, the ejection fraction recovered. The patient recovered and was alive at 1-year follow-up, without relevant limitations to his quality of life. Discussion and Conclusion: The article further discusses the use of plasma exchange for immune checkpoint inhibitor-associated myocarditis based on a review of literature. We conclude that patients showing no improvement after steroid therapy for immune checkpoint inhibitor-related myocarditis should be evaluated for plasma exchange, which appears to be an effective treatment option.
- Schiopu, S. R. I.
- Käsmann, L.
- Schönermarck, U.
- Fischereder, M.
- Grabmaier, U.
- Manapov, F.
- Rauch, J.
- Orban, M.
Keywords
- Mesothelioma
- immune check inhibition
- myocarditis
- plasma exchange
- treatment related toxicity
- (Available at http://dx.doi.org/10.21037/tlcr-20-1095). MO received speaker
- honoraria and travel compensations from Abbott Medical, AstraZeneca, Abiomed, Bayer
- vital, BIOTRONIK, Bristol-Myers Squibb, CytoSorbents, Daiichi Sankyo Deutschland,
- Edwards Lifesciences Services, Sedana Medical, outside the submitted work. U
- Schönermarck reports grants, personal fees and non-financial support from Alexion,
- as well as grants and personal fees from Chemocentryx, outside the submitted work.
- The other authors have no conflicts of interest to declare.
